about us


Accelovance's commitment to providing quality services starts with our people. Our team members are passionate about their work and are dedicated to fulfilling each client's requirements in a timely, accurate, well managed and cost-effective manner.

Our executive management team combines entrepreneurial business talents, clinical and medical expertise, and biotech industry experience to effectively lead the vision of the company. The following individuals are the foundation of Accelovance's ability to the address clinical needs and business objectives of those we serve.

Stephen J. Trevisan, President and CEO, Accelovance

Steve_Trevisan.jpgMr. Trevisan is an entrepreneur who has founded four companies, including Accelovance, Inc. in 2005. Prior to Accelovance, Mr. Trevisan founded TherImmune Research Corporation, a Contract Research Organization (CRO) specializing in preclinical and early stage clinical drug development services for the pharmaceutical, biotechnology, and government markets. He also founded CommSys Corporation, a provider of outsourced billing services to the telecommunications industry. In 1987, Mr. Trevisan co-founded his first company, National Clinical Research Centers (NCRC), a CRO specializing in Phase II-IV clinical studies. NCRC deployed a unique method for running clinical trials which was successful in reducing the timeframe in conducting multi-center trials in broad-based indications. Each of Mr. Trevisan's prior companies maintained year-over-year growth and were ultimately acquired by public companies.



Joseph W. Angle Jr., Chief Financial Officer

Joe_Angle.jpgMr. Angle leads the financial, legal, and administrative functions for Accelovance, Inc. Since 1995, Mr. Angle has honed his experience in the drug development, preclinical, and clinical research industries. He previously co-founded several companies with Accelovance CEO, Stephen J. Trevisan, including TherImmune Research Corporation, CommSys Corporation, and National Clinical Research Centers (NCRC). Mr. Angle served in a similar capacity at Computer Sciences Corporation, as part of the Health and Administrative Services Division based in Washington, DC, a claims processing service organization for the federal and state governments. Mr. Angle helped manage each company to profitability and year-over-year revenue growth.




Vita Lanoce, MS, Chief Operating Officer

Vita-Formatted.pngMs. Lanoce leads the Global Clinical Operations organization.  Ms. Lanoce ensures operational excellence is achieved by applying high industry standards, policies, systems and processes across the organization.  Ms. Lanoce has more than 22 years of experience in the clinical research industry. Prior to joining Accelovance, Ms. Lanoce had a 15 year tenure with Radiant Development where she held positions of increasing responsibility including Site Director, Director Regional Operations, Director Operations, and Vice President Clinical Operations. Prior to joining Radiant Development, Ms. Lanoce was the Managing Partner and Director of Clinical Operations for two clinical research facilities located in Stuart and Lake Worth, Florida. Ms. Lanoce has held a variety of positions in the biopharmaceutical industry including Clinical Scientist at Bristol-Meyers Squibb and Regional Manager for Covance. Ms. Lanoce holds a Master's of Science in Biomedical Engineering from Rutgers University and a Bachelor of Arts in Biology from Manhattanville College.



Harish Dave, MD, Chief Medical Officer

Harish_Dave_CMO.jpgDr. Dave leads Accelovance's Medical Affairs & Drug Safety group.  Dr. Dave has 25+ years of Phase I-IV clinical research experience including the conduct of over a 100 studies with a focus on hematology, oncology and transplantation as well as other areas of internal medicine. Dr. Dave provides integrated drug development and therapeutic advice, management of clinical trials, and expertise and due diligence for biotech, small, medium and large pharma and VC companies. He has basic science expertise in gene regulation, gene therapy and tumor immunology, clinical and academic expertise in hematology including coagulation disorders, oncology and transplantation, and industry experience in hematology/oncology drug development from pre-clinical to phase IV space and in biosimilars/biobetters and immunotherapeutics.

Prior to joining Accelovance, Dr. Dave held positions at Quintiles, George Washington University Medical Center and VA Medical Center in Washington, DC and NIH in Bethesda, MD. Dr. Dave holds a MB, ChB from the University of Sheffield and a MBA from the TRIUM program (jointly awarded by NYU, London School of Economics and HEC).   

Jamie Oliver, PharmD, Chief Science Officer

Jamie_Oliver.jpgDr. Oliver serves as our Chief Science Officer, leveraging his strategic, scientific, and industry experience to guide Sponsor product development. Prior to joining the Accelovance team in 2013, Dr. Oliver was the Chief Executive Officer at Phage Pharmaceuticals, Inc. and prior to that was a Principal at Trinity Drug Partners, LLC. Dr. Oliver has amassed significant clinical research experience in both preclinical and clinical experimentation in academia and the pharmaceutical industry. Dr Oliver has strong therapeutic experience in the areas of oncology, hematology, vaccines, nutritional support, cytokines regulation, infectious diseases, immunopharmacology, renal disease, and transplantation. Dr. Oliver has served on the executive management team of both public and private pharmaceutical companies in a Vice President/COO role. He has served on the clinical faculty of Mercer University, Emory University, and the University of North Carolina. He also was a collaborative researcher with the Centers for Disease Control and Prevention, Hospital Infections Division. Dr. Oliver received his Doctor of Pharmacy degree from Mercer University in Atlanta. He has published a number of peer-reviewed articles in the area of immunopharmacology and oncology and is a member of the American Society of Clinical Oncology.  

Mary Mattes, EVP, Global Biometrics & Information Technology

Mary_Mattes.jpgAs Accelovanc'es Executive Vice President, Global Biometrics & Information Technology, Ms. Mattes is responsible for the strategy development and execution of the resources, systems, and processes required to deliver clinical trial data. She oversees the clinical data managers, database programmers, statistical programmers, and biostatisticians. Additionally, Ms. Mattes is responsible for the Information Technology infrastructure of the corporation including SaaS vendor management, MSP management, and alignment of clinical technologies to support CRO and SMO delivery.  She has more than 19 years of experience in clinical contract research organizations supporting pharmaceutical and biotech company’s Phase I-IV clinical trial research in the areas of project management, data management, technology implementation, and user support in the regulatory environment.

Prior to joining Accelovance, Ms. Mattes worked at PRA Health Sciences for 15 years, the last four years as their department head of strategic client delivery for Clinical Informatics which included all biometric services and technology. She holds a Bachelor of Arts in Biology with a concentration in Genetics from the College of Saint Rose in Albany, NY.  

Nigel Trim, Managing Executive Director of Accelovance Europe

Nigel_Trim.jpgNigel Trim is the Managing Director of Accelovance Europe.  Nigel is a pharmacologist by training and has spent more than 30 years working in the industry across multiple therapeutic areas in small molecule pharmaceuticals, biological, biotechnology, and medical device products. Nigel’s experience includes clinical programs in Europe and CEE, North America, North Africa, and Asia Pacific areas. He founded Matrix Contract Research, Ltd and Matrix Clinical Solutions and following their acquisition remained as Managing Director of Novella Clinical Europe for three years. Nigel recently held the position of Interim Managing Director of the AIM listed CRO Venn Life Sciences and has also worked for Pharmaventures, consulting on CRO M&A. He was the Executive Chairman of Altair Clinical, Ltd., prior to its acquisition by Accelovance in 2015 and has been the Director of a number of other companies.



Jamie Chorlton, SVP, Clinical Operations Europe

Jamie Chorlton_new.pngJamie Chorlton is the Senior Vice President, Clinical Operations Europe. Jamie was a cofounder and Chief Executive Officer at Altair Clinical, Ltd., prior to its acquisition by Accelovance in January, 2015. Before launching Altair Clinical, Jamie served as Chief Operating Officer at Venn Life Sciences, Ltd. Jamie has also held senior managerial roles at Novella Clinical, Ltd., and previously Matrix Contract Research Ltd., where he played an instrumental role in the growth of both organizations. In addition to a decade in the CRO industry, Jamie has also served in operational roles in the biotech and pharma industries, working at Oxxon Therapeutics and Wyeth Research respectively. Jamie has a Bachelor of Science degree in Biomedical Technology from Sheffield Hallam University.




Wendy Wang MD, PhD, Managing Director Accelovance China

Wendy_Wang.jpgDr. Wendy (Wen-Ying) Wang is the Managing Director at Accelovance China. As Head of Accelovance China, Dr. Wang helps western pharmaceutical companies with global clinical trial registration, import drug registration, regulatory consultancy, clinical site management, and project management of multi-center global clinical trials in China. Dr. Wang has broad experiences in research, technical, sales, quality, medical and regulatory affairs within the biotechnology and pharmaceutical industries in the areas of bioactive enzymes, medicines, and vaccines in Greater China and Asia Pacific regions. Dr. Wang earned her clinical medicine degree from Shandong Weifang Medical College, Master's degree in gastroenterological physiology from Peking Union Medical College, and her PhD in the regulation of angiogenesis by vascular endothelial growth factor from the University of Bristol in the United Kingdom.



Jeff Levin, Vice President, Human Resources

Jeff_Levin.jpgMr. Levin is the Vice President of Human Resources and is responsible for providing leadership in the development, communication, and execution of a human resource strategies in support of organizational goals. Among his many areas of focus, Mr. Levin leads initiatives for talent management, compensation, and employee and leadership development. He also directs the day-to-day administration of benefits and employee relations. Mr. Levin has more than 15 years’ experience as a human resources professional in the life sciences sector. Prior to joining Accelovance, Mr. Levin was with Cardiocore for seven years and Medimmune for seven years as a Director of Human Resources. Mr. Levin holds a BS degree from the University of Maryland.




Michael Keens, EVP, Global Business Development & Proposals

Mike_Keens.jpgMr. Keens leads the corporate business development, proposals and marketing organizations at Accelovance, leveraging over 16 years of clinical trial experience across academic medical centers, consultancies, emerging biotechnology companies, and large global CROs. Before joining Accelovance, Mr. Keens was responsible for developing strategic and preferred partnerships with pharmaceutical and biotechnology companies for two large global CROs both as a team leader and individual contributor. Prior to working in business development, Mr. Keens held clinical and project management responsibilities, ultimately as an Oncology Program Manager, collaborating with a large biotechnology company across a number of development compounds (Phases I-III). Mr. Keens received his Master's Degree in Public Health from The University of Virginia and his Bachelor's Degree in Biology/Psychology (double major) from James Madison University.



About Accelovance

Accelovance is an award-winning, niche CRO focused primarily in oncology, vaccines, and general medicine. Accelovance operates three core service divisions:


Our executive management team combines entrepreneurial business talents, clinical and medical expertise, and biotech industry experience.